Miguel Cordon · · 1 min readSingapore-based diagnostics startup banks $5m to commercialize first product
Singapore-based medical diagnostics company One BioMed raised US$5 million in a series A round led by local investment firm Biopath Ventures and US early-stage venture capital firm Arch Venture Partners.
Photo credit: Michal Jarmoluk
Seeds Capital, Enterprise Singapore’s investment arm , also participated in the round.
A spin-off of ASTAR in 2016, One BioMed is developing digital health platforms for diagnostic testing. It plans to use the fresh funds to commercialize its first product, which is an automated sample preparation device for purification and isolation of nucleic acids from a range of samples.
The company said the device serves as the foundation for its next-generation platforms.
In addition to the funding, Biopath Ventures founding partners Joseph Jeong and Nick Roelofs will be joining One BioMed’s board.
Editing by Charmaine de Lazo
(And yes, we’re serious about ethics and transparency. More information here.)
Stay updated on the go with our mobile app.
Get latest insights with smoother, more personalized experience through TIA mobile app.
